Patients with T2DM without present CVD but with already present risk CV-factors: case reports
Authors:
Valéria Mokrá 1; Monika Masarovičová 2; Zbynek Schroner 3
Authors‘ workplace:
DIA WAY, s. r. o., ambulancia diabetológie a porúch metabolizmu výživy, Bojnice
1; M. K. U. MED, s. r. o., ambulancia diabetológie, porúch látkovej premeny a výživy, Bratislava Ružinov
2; Lekárska fakulta, Univerzita Pavla Jozefa Šafárika v Košiciach
3
Published in:
Diab Obez 2025; 25(1): 47-49
Category:
Case studies
Sources
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J 2023; 44(39): 4043–4140. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehad192>. Erratum in: Eur Heart J 2023; 44(48): 5060. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehad774>. Erratum in: Eur Heart J 2024; 45(7): 518. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehad857>.
Mosenzon O, Wiviott SD, Cahn A et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol 2019; 7(8): 606–617. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(19)30180–9>. Erratum in: Lancet Diabetes Endocrinol 2019; 7(8): e20. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(19)30221–9>.
Labels
Diabetology ObesitologyArticle was published in
Diabetes and obesity
2025 Issue 1
Most read in this issue
- Tirzepatide – a dual incretin agonist in the management of type 2 diabetes mellitus: a review of evidence from the SURPASS trials
- The addictive potential and the neurobiological mechanisms underlying the consumption of hyperpalatable foods: Does food addiction exist?
- Patients with T2DM without present CVD but with already present risk CV-factors: case reports
- Editoriál